NASDAQ:AMRS

Amyris Stock Forecast, Price & News

$11.29

+0.84 (+8.04 %)

(As of 01/15/2021 08:00 PM ET)

Add

Compare

Today's Range

$10.11

Now: $11.29▼

$11.76

50-Day Range

$2.63

MA: $5.30▼

$10.45

52-Week Range

$1.40

Now: $11.29▼

$11.78

Volume585,080 shs

Average Volume5.76 million shs

Market Capitalization$2.70 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.04

Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

MarketRank^™

Overall MarketRank^™

1.14 out of 5 stars

1.5 Analyst's Opinion

Consensus Rating
Amyris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.12, Amyris has a forecasted downside of 37.0% from its current price of $11.29.
Amount of Analyst Coverage
Amyris has only been the subject of 3 research reports in the past 90 days.

1.9 Community Rank

Outperform Votes
Amyris has received 323 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Amyris has received 515 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Amyris has received 61.46% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote “Outperform” if you believe AMRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Amyris does not currently pay a dividend.
Dividend Growth
Amyris does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amyris insiders have not sold or bought any company stock.
Percentage Held by Insiders
39.70% of the stock of Amyris is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.46% of the stock of Amyris is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Amyris are expected to grow in the coming year, from ($1.59) to ($0.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amyris is -5.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amyris is -5.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Industrial organic chemicals

Sub-IndustryOil & Gas Refining & Marketing

SectorBasic Materials

Current SymbolNASDAQ:AMRS

Previous Symbol

CUSIP03236M10

CIK1365916

Webamyris.com

Phone510-450-0761

Employees561

Debt

Debt-to-Equity RatioN/A

Current Ratio1.27

Quick Ratio0.91

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$152.56 million

Price / Sales17.70

Cash FlowN/A

Price / Cash FlowN/A

Book Value($2.17) per share

Price / Book-5.20

Profitability

EPS (Most Recent Fiscal Year)($2.72)

Net Income$-242,770,000.00

Net Margins-223.41%

Return on EquityN/A

Return on Assets-149.25%

Miscellaneous

Outstanding Shares239,210,000

Market Cap$2.70 billion

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$11.29

+0.84 (+8.04 %)

(As of 01/15/2021 08:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Amyris (NASDAQ:AMRS) Frequently Asked Questions

How has Amyris' stock price been impacted by Coronavirus (COVID-19)?

Amyris' stock was trading at $2.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMRS stock has increased by 281.4% and is now trading at $11.29.
View which stocks have been most impacted by COVID-19.

Is Amyris a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amyris stock.
View analyst ratings for Amyris or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Amyris?

Wall Street analysts have given Amyris a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amyris wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Amyris.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) posted its quarterly earnings results on Tuesday, November, 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.20. The biotechnology company had revenue of $34.26 million for the quarter, compared to analysts' expectations of $38.76 million.
View Amyris' earnings history.

When did Amyris' stock split? How did Amyris' stock split work?

Amyris's stock reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for AMRS?

4 Wall Street analysts have issued 1 year target prices for Amyris' shares. Their forecasts range from $3.35 to $9.00. On average, they expect Amyris' stock price to reach $7.12 in the next twelve months. This suggests that the stock has a possible downside of 37.0%.
View analysts' price targets for Amyris or view Wall Street analyst' top-rated stocks.

Who are some of Amyris' key competitors?

Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), Renewable Energy Group (REGI), World Fuel Services (INT), Clean Energy Fuels (CLNE), Delek US (DK), PBF Energy (PBF), Gevo (GEVO), Green Plains (GPRE), REX American Resources (REX), Adams Resources & Energy (AE) and CVR Energy (CVI).
View all of AMRS's competitors.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

Who are Amyris' key executives?

Amyris' management team includes the following people:

Mr. John G. Melo, Pres, CEO & Director (Age 55, Pay $1.15M)
Mr. Eduardo Alvarez, Chief Operating Officer (Age 57, Pay $665.19k)
Ms. Kathleen Valiasek, Chief Bus. Officer (Age 57, Pay $588.08k)
Mr. Hermanus Kieftenbeld, Chief Financial Officer (Age 55)
Mr. Anthony Hughes, Chief Accounting Officer (Age 56)
Mr. Peter DeNardo, Sr. Director of Investor Relations & Corp. Communications
Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 55)
Ms. Beth Baker Bannerman, Sr. VP of Corp. Communications & Engagement
Ms. Christine Ofori, Chief People Officer
Mr. Charles Kraft, Sr. VP of Global Manufacturing & Process Devel.

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $11.29.

How big of a company is Amyris?

Amyris has a market capitalization of $2.70 billion and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 561 workers across the globe.

What is Amyris' official website?

The official website for Amyris is amyris.com.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here